HOME >> BIOLOGY >> NEWS
Preclinical study shows chronic stress agitates ovarian cancer; reducing stress slows tumor growth

Houston -- When mice with ovarian cancer are stressed, their tumors grow and spread more quickly, but that effect can be blocked using a medication commonly prescribed for heart disease, according to a preclinical study by researchers at The University of Texas M. D. Anderson Cancer Center.

The finding, published in the journal Nature Medicine, now available on-line, provides the first measurable link between psychological stress and the biological processes that make ovarian tumors grow and spread. Specifically, the researchers showed that stress hormones bind to receptors directly on tumor cells and, in turn, stimulate new blood vessel growth and other factors that lead to faster and more aggressive tumors.

"This study provides a new understanding of how chronic stress and stress factors drive tumor growth," says Anil Sood, M.D., associate professor of gynecologic oncology and cancer biology and director of ovarian cancer research.

In fact, when the researchers blocked the stress hormone receptors in their experimental system using a heart disease drug called propranolol, also known as a "beta blocker," they were able to stop the negative effects of stress on tumor growth. The researchers used the beta blocker because the same hormone receptors, called beta adrenergic receptors, are found in the heart and normally work to maintain blood flow.

"The concept of stress hormone receptors directly driving cancer growth is very new," says Sood, the study's senior author. "Not much had been known about how often these receptors are expressed in cancer, and more importantly, whether they had any functional significance. Our research opens a new area of investigation."

The research began when Sood and his colleague Susan Lutgendorf found an association between ovarian cancer patients who reported high levels of stress in their lives and an increase in a factor that stimulates blood vessel growth in tumors. By contrast, patients who had more soc
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
23-Jul-2006


Page: 1 2 3

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Preclinical study of a new brain tumor therapy
3. New study warns limited carbon market puts 20 percent of tropical forest at risk
4. Clones on task serve greater good, evolutionary study shows
5. Pollution causes 40 percent of deaths worldwide, study finds
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. New study suggests Concord grape juice may provide protection against breast cancer
8. In limiting life span, study finds booming bacteria innocent
9. Multicenter study nets new lung tumor-suppressor gene
10. MIT study: Maturity brings richer memories
11. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... According to a report by Transparency Market ... due to the presence of a large pool of participants; however, ... , and Sigma-Aldrich, compete with each other in this market. With ... than 76% of this market in 2016.  ... As of now, a large number of ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
Breaking Biology Technology:
Cached News: